6533b831fe1ef96bd12990c3
RESEARCH PRODUCT
Diabetic microangiopathy: Pathogenetic insights and novel therapeutic approaches.
Carmela Rita BalistreriRaffaele De CaterinaRosalinda MadonnaYong-jian Gengsubject
0301 basic medicineGlycation End Products AdvancedPhysiologyDiabetes retinopathyGlycation End ProductsDiseaseFibroblast growth factorHMGB1DiabeteMicrocirculationCapillary Permeability03 medical and health sciencesGlycationDiabetes mellitusmedicineSettore MED/05 - Patologia ClinicaAnimalsHumansCellular and molecular pathways; Diabetes; Diabetes retinopathy; Microangiopathy; Physiology; Molecular Medicine; PharmacologyNeovascularizationPharmacologyPathologicbiologyNeovascularization Pathologicbusiness.industryMicrocirculationMicroangiopathyDiabetesToll-Like Receptorsmedicine.diseasePrognosisCellular and molecular pathways; Diabetes; Diabetes retinopathy; Microangiopathy; Animals; Capillary Permeability; Diabetic Angiopathies; Glycation End Products Advanced; Humans; Inflammation Mediators; Microcirculation; Microvessels; Neovascularization Pathologic; Oxidative Stress; Prognosis; Signal Transduction; Toll-Like ReceptorsOxidative Stress030104 developmental biologyCellular and molecular pathwaysMicroangiopathyImmunologyMicrovesselsbiology.proteinMolecular MedicineAdvancedCellular and molecular pathwayInflammation MediatorsbusinessDiabetic AngiopathiesRetinopathySignal Transductiondescription
Diabetic microangiopathy, including retinopathy, is characterized by abnormal growth and leakage of small blood vessels, resulting in local edema and functional impairment of the depending tissues. Mechanisms leading to the impairment of microcirculation in diabetes are multiple and still largely unclear. However, a dysregulated vascular regeneration appears to play a key role. In addition, oxidative and hyperosmolar stress, as well as the activation of inflammatory pathways triggered by advanced glycation end-products and toll-like receptors, have been recognized as key underlying events. Here, we review recent knowledge on cellular and molecular pathways of microvascular disease in diabetes. We also highlight how new insights into pathogenic mechanisms of vascular damage in diabetes may indicate new targets for prevention and treatment.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2017-01-01 | Vascular pharmacology |